Core Insights - Scott+Scott Attorneys at Law LLP is investigating Alvotech for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1][3] - Alvotech develops and manufactures biosimilar medicines, focusing on therapeutic areas such as autoimmune, eye, bone disorders, and cancer [2] - On November 2, 2025, Alvotech received a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA) for AVT05, a biosimilar candidate to Simponi®, indicating deficiencies that must be resolved before approval [3] - Following the FDA's announcement, Alvotech's stock price dropped approximately 34%, closing at $5.03 on November 3, 2025 [3]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Marex (MRX) To Contact Him Directly To Discuss Their Options If you purchased or stock in Marex and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized stockholder ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Sensus Healthcare, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - The investigation is focused on whether Sensus has engaged in any unlawful activities that may have affected its stockholders [1][2]. Financial Performance - On August 7, 2025, Sensus reported a second quarter GAAP earnings-per-share of -$0.06, missing estimates by $0.09 - Revenue for the same period was $7.3 million, reflecting a year-over-year decline of 20.7% and missing estimates by $2 million - The revenue decline was attributed to a lower number of units sold to a large customer, although there was some growth in recurring revenue from Fair Deal Agreements [6]. Stock Price Reaction - Following the financial results announcement, Sensus's stock price dropped by $1.89 per share, or 35.32%, closing at $3.46 per share on August 8, 2025 [6]. Next Steps for Investors - Investors who purchased Sensus shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their legal rights and potential claims [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation across the United States [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Avita Medical, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Avita has engaged in practices that may have harmed investors, particularly in light of recent financial disclosures [1][2]. Financial Performance - On August 7, 2025, Avita reported a significant backlog in unpaid provider claims for its Recell procedures, which negatively impacted demand in the first half of the year [6]. - The backlog was attributed to contractors from the Centers for Medicare & Medicaid Services failing to assign adequate pricing and timely adjudication of claims, leading to uncertainty among providers [6]. - Following this announcement, Avita's stock price fell by $1.13, or approximately 21%, from $5.38 to $4.25 per share [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against J.M. Smucker Company for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on the financial performance of Smucker, particularly following the acquisition of Hostess Brands for approximately $5.5 billion, which included $2.4 billion recorded as goodwill [6]. - Recent financial results have shown significant declines in net sales and substantial impairment charges, raising concerns about the company's business practices and financial health [6]. Financial Performance - On February 27, 2025, Smucker reported a Q3 2025 net sales decrease of 8% in the Sweet Baked Snacks segment, alongside a $794 million impairment charge related to goodwill and a $208 million impairment charge for the Hostess Brand trademark [6]. - On June 10, 2025, the company announced a further decline of 14% in Q4 2025 net sales for the Sweet Baked Snacks segment, with an additional $867 million impairment charge for goodwill and a $113 million impairment charge for the Hostess Brand trademark [6]. - Following these announcements, Smucker's share price fell by $17.44, or approximately 15.59%, closing at $94.41 per share on June 10, 2025 [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Abacus Global Management, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - A report by Morpheus Research on June 4, 2025, accused Abacus of being involved in a life settlements accounting scheme, leading to a stock price decline of over 21% [2]. Next Steps - Abacus shareholders who have suffered losses or have information regarding the claims are encouraged to contact Bragar Eagel & Squire for further assistance [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a law firm recognized nationally, representing investors in various complex litigations across state and federal courts [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Simulations Plus, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - The law firm is reaching out to Simulations Plus stockholders who may have suffered losses and encourages them to discuss their legal rights [1][3]. Financial Performance - Simulations Plus reported third fiscal quarter sales of $20.4 million, missing the consensus estimate of $20.9 million [6]. - The company experienced a net loss of $67.3 million and a diluted loss per share of $3.35, which included a non-cash impairment charge of $77.2 million, compared to a net income of $3.1 million and diluted earnings per share of $0.15 for the same period in 2024 [6]. - The fiscal 2025 adjusted earnings guidance was revised down to $0.93 to $1.06 from a previous range of $1.07 to $1.20 [6]. Operational Changes - In June, Simulations Plus initiated a restructuring of its operations, which included workforce reductions and cost-cutting measures aimed at improving operational efficiency and reducing expenses [6]. Stock Market Reaction - Following the financial results announcement, Simulations Plus's stock price fell by $4.50 per share, or 25.76%, closing at $12.97 per share on July 15, 2025 [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Barnes & Noble Education, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3]. Group 1: Investigation Details - The investigation is prompted by a delay in Barnes & Noble's annual report for the fiscal year ended May 3, 2025, due to an ongoing investigation into the recording of digital sales costs [3]. - Early findings suggest that Barnes & Noble may have overstated accounts receivable by up to $23 million and expects to report at least one material weakness related to manual journal entries [3]. Group 2: Market Reaction - Following the news of the investigation, Barnes & Noble's stock price fell by $2.36 per share, representing a decline of 21.02%, closing at $8.87 per share on July 21, 2025 [4]. Group 3: Legal Support - Investors who have suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for assistance [1][5].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against James Hardie Industries plc for possible violations of federal securities laws and unlawful business practices [2] - James Hardie reported a 29% decline in first-quarter profit for the period ending June 30, 2025, and projected lower-than-expected earnings for fiscal 2026 due to high borrowing costs [3] Financial Performance - The company experienced a significant drop in its American Depositary Receipt (ADR) price, which fell by $9.79 per ADR, or 34.44%, closing at $18.64 per ADR on August 20, 2025, following the announcement of its financial results [3] Legal Context - Investors who suffered losses from purchasing or acquiring James Hardie shares are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights [1][4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Marex Group PLC for possible violations of federal securities laws and unlawful business practices, following a report that raised serious concerns about the company's financial integrity [2][3]. Group 1: Investigation and Allegations - The law firm is encouraging investors who suffered losses in Marex to contact them to discuss their legal rights [1][4]. - NINGI Research published a report on August 5, 2025, claiming that Marex has been involved in a multi-year accounting scheme, utilizing opaque off-balance-sheet entities and misleading disclosures to hide significant losses and inflate profits [3]. - Following the release of the report, Marex's stock price dropped by $2.33, or 6.19%, closing at $35.31 per share [3]. Group 2: Company Background - Marex Group PLC is publicly traded on NASDAQ under the ticker MRX [2]. - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various complex litigations [5].